Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799157 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
A Phase 2 study, sponsored by Veradermics.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT05799157: Completed Phase 2 study, sponsored by Veradermics.
NCT05799157 is a Phase 2 study that has completed, run by Veradermics. The registered enrollment target is 153 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05799157, a Phase 2 study, has completed, sponsored by Veradermics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Primary Outcome
Complete clinical resolution is defined as the target lesion with area = 0.
Interventions
- DRUG VDMN-21 Patch Low Dose
- DRUG VDMN-21 Patch High Dose
- DRUG Vehicle Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-02-25 |
| Phase | Phase 2 |
What the finished NCT05799157 record still lists
NCT05799157 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 3 interventions - of which VDMN-21 Patch Low Dose is the first listed.
NCT05799157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05799157 about?
NCT05799157 is a clinical study titled "Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts". This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
What is the current status of trial NCT05799157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2023-02-28. Estimated completion is 2025-02-25.
What interventions are being tested in trial NCT05799157?
The interventions under investigation include: VDMN-21 Patch Low Dose (DRUG), VDMN-21 Patch High Dose (DRUG), Vehicle Patch (DRUG).
Who is sponsoring clinical trial NCT05799157?
This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05799157's enrollment target sits among peer trials
153 449th of 2000 higher than 1,549 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI